Score Patentability Before R&D Commits: The AI Pharma IP Stack That Turns Patent Risk into Portfolio Alpha
Part I: The Strategic Imperative – Patent Risk as a Financial Variable {#part-i} The $2.6 Billion Problem No Pipeline Model […]
Amgen v. Sanofi: The Definitive Technical Playbook on Biologic Patent Enablement, Antibody Claim Strategy, and the Biosimilar Challenger’s Advantage
1. The Patent Bargain, Recalibrated: What the Ruling Actually Did On May 18, 2023, the U.S. Supreme Court issued a
Pharma IP Benchmarking: The Complete Playbook for Protecting Pipeline Value Before a Competitor Does
Why IP Benchmarking Is a Revenue Function, Not a Legal One A composition of matter patent on a new drug
Unveiling the Secrets Behind Big Pharma’s Patent Thickets
Section 1: The Broken Bargain: How a 20-Year Monopoly Became a 40-Year Rent The patent system’s foundational premise is blunt:
Unveiling the Secrets Behind Big Pharma’s Patent Thickets Read Post »
Patent Prosecution Highway for Drug Patents: The Complete Strategic Playbook
1. Why Prosecution Speed Is a Balance Sheet Issue The 20-year patent term granted under 35 U.S.C. Section 154 is
Patent Prosecution Highway for Drug Patents: The Complete Strategic Playbook Read Post »
Patent Cliff Playbook: Out-License Mature Drug Assets Before LOE Destroys Your P&L
Who this is for: Business development leads managing loss-of-exclusivity (LOE) timelines, IP counsel evaluating secondary patent thickets, portfolio managers modeling
Patent Cliff Playbook: Out-License Mature Drug Assets Before LOE Destroys Your P&L Read Post »
Biosimilar First-Mover Advantage: What the Adalimumab Market Actually Taught Us
The biosimilar first-mover question has a clean theoretical answer and a messy empirical one. Theory says: get to market first,
Biosimilar First-Mover Advantage: What the Adalimumab Market Actually Taught Us Read Post »
How Technology Is Redrawing the Map for Generic Drug Development: AI/ML, Continuous Manufacturing, IP Valuation, and the Competitive Dynamics Shaping the ANDA Landscape Through 2030
Executive Summary Generic pharmaceutical companies face a structural cost squeeze that has worsened since 2016. Teva, Mylan, and Sun Pharma
The Open Pharma Revolution: A Strategic Deconstruction of Collaborative Drug Discovery Business Models
A deep-dive pillar page for pharma/biotech IP teams, R&D leads, and institutional investors. Part 1: The R&D Productivity Crisis —
